Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Avenir Wellness Solutions, Inc. (CURR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity"
07/28/2023 10-Q Quarterly Report for the period ended March 31, 2023
07/28/2023 10-K Annual Report for the period ended December 31, 2022
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
04/20/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/08/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Employment Agreement, by and between Avenir Wellness Solutions, Inc. and Nancy Duitch"
01/17/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Certificate of Amendment of Certificate of Incorporation",
"CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc."
11/21/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
09/02/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/19/2022 8-K Quarterly results
08/16/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/28/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/01/2022 10-K Annual Report for the period ended December 31, 2021
01/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Forbearance Agreement"
12/03/2021 8-K Quarterly results
11/15/2021 10-Q Quarterly Report for the period ended September 30, 2021
08/16/2021 10-Q Quarterly Report for the period ended June 30, 2021
05/17/2021 10-Q Quarterly Report for the period ended March 31, 2021
04/29/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
03/31/2021 10-K Annual Report for the period ended December 31, 2020
02/25/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
01/06/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue™ OXNARD, Calif.- Jan. 5, 2021 -- CURE Pharmaceutical Holding Corp , a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration has approved an Investigational New Drug application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate for the treatment of erectile dysfunction . CURE is seeking approval of this product via the 505 regulatory pathway to expedite the U.S. approval process. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfi..."
12/15/2020 8-K/A Financial Statements and Exhibits
Docs: "Unaudited Condensed Financial Statements of The Sera Labs, Inc. for the nine months ended September 30, 2020 and Audited Financial Statements of The Sera Labs, Inc. for the year ended December 31, 2019",
"Unaudited Pro Forma Combined Financial Statements of Cure Pharmaceutical Holding Corp. as of and for the nine months ended September 30, 2020, and as of and for the year ended December 31, 2019"
12/10/2020 EFFECT Form EFFECT - Notice of Effectiveness:
12/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "About SeraLabs SeraLabs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. SeraLabs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names SeraRelief™, Seratopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. SeraLabs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, SeraLabs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level ..."
11/30/2020 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/25/2020 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy